Skip to main content
main-content

01.04.2015 | Original Research Article | Ausgabe 4/2015

Clinical Pharmacokinetics 4/2015

Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis

Zeitschrift:
Clinical Pharmacokinetics > Ausgabe 4/2015
Autoren:
Stefanie Hennig, Franziska Holthouse, Christine E. Staatz
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s40262-014-0211-9) contains supplementary material, which is available to authorized users.

Abstract

Background and Objectives

Several dosage adjustment methods are currently available to individualize intravenous tobramycin dosing. This study compared different methods in terms of their recommendations for dosage adjustment, their estimation of patients’ pharmacokinetic parameter values and their ability to predict subsequent observed tobramycin concentrations following once-daily tobramycin treatment in children and adolescents with cystic fibrosis.

Methods

Retrospective data from 172 patients treated at the Royal Children’s Hospital (Brisbane, QLD, Australia) were analysed. To be included in the analysis, each patient had to have at least one pair of tobramycin plasma concentration–time measurements recorded over a dosing interval. One or both of the concentrations in the paired set were applied in each of the following dosage adjustment methods: (i) the Therapeutic Guidelines Aminoglycoside nomogram; (ii) the Massie nomogram; (iii) log-linear regression analysis; and two Bayesian forecasting software programs: (iv) TCIWorks and (v) DoseMe. All methods were compared in regard to their recommendations for tobramycin dosage adjustment. The latter three methods were also examined in terms of estimated pharmacokinetic parameter values and their ability to predict subsequent observed tobramycin concentrations.

Results

The Therapeutic Guidelines nomogram recommended significantly greater mean doses for dosage adjustment (27.0 mg/kg) compared with all other methods (p ≤ 0.01), which gave similar mean dose recommendations (11.6–14.6 mg/kg); however, >20 % differences in doses on an individual level were seen on 20–35 % of occasions across all methods. The log-linear regression analysis method and the two Bayesian forecasting methods (TCIWorks and DoseMe) showed negligible bias but imprecision of around 20 % in predicting subsequent observed tobramycin concentrations. The Bayesian forecasting methods showed no significant difference in mean dose recommendations when using either one or two concentration measurements but increased imprecision in predicting subsequent observed tobramycin concentrations.

Conclusion

The log-linear regression method and Massie nomogram are likely to be suitable alternative methods for tobramycin dosage adjustment when Bayesian forecasting software is unavailable. The Therapeutic Guidelines nomogram should not be used to aid dose adjustment of tobramycin therapy in children with cystic fibrosis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Zusatzmaterial
Supplementary material 1 (PDF 374 kb)
40262_2014_211_MOESM1_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2015

Clinical Pharmacokinetics 4/2015 Zur Ausgabe